Kinase inhibitors attract attention as oral rheumatoid arthritis drugs.
Opar
Alisa
A
D000284:Administration, Oral; D000631:Aminopyridines; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D009025:Morpholines; D010078:Oxazines / Q000494:pharmacology / Q000627:therapeutic use; D010880:Piperidines; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use
D000631:Aminopyridines; D009025:Morpholines; D010078:Oxazines; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib; C523665:fostamatinib